Archives
Bulevirtide Linked to Decline in Hepatitis D Virus RNA Levels
Normalization of alanine aminotransferase also seen with bulevirtide 2- or 10-mg
Pegozafermin Leads to Improvements in Fibrosis in NASH
Improvements also seen in NASH resolution with pegozafermin 15 or 30 mg weekly, or 44 mg every two weeks
ADA: Childhood Hyperglycemia Linked to Future Microvascular Complications
Higher HbA1c, two-hour plasma glucose linked to significantly increased risk of retinopathy in children without T2D
ADA: Reductions in Body Weight With Retatrutide for Obesity
Substantial reductions seen in body weight with retatrutide treatment for 48 weeks in phase 2 trial
Review Looks at Psychological Burden of Children, Young Adult Cancer Patients
Children, adolescent, and young adult patients with cancer at increased lifetime risk of diagnosis or increased severity of depression, anxiety, and psychotic disorders
ADA: Once-Weekly Icodec Superior for Reduction in HbA1c
Noninferior and superior reduction in HbA1c with one-weekly icodec versus once-daily degludec in insulin-naive type 2 diabetes patients
ADA: Once-Daily Semaglutide Superior for Reduction in Body Weight
Superior and clinically meaningful reduction in body weight in adults with overweight, obesity without type 2 diabetes
ENDO: Women With Polycystic Ovary Syndrome Experience More Body Image Concerns
Authors say findings show need for body image screening in clinical practice
ADA: Once-Weekly Tirzepatide Leads to Weight Loss in Patients With Obesity, T2D
Substantial and clinically meaningful reductions in body weight seen for adults with obesity and type 2 diabetes
ADA: Bempedoic Acid Cuts MACE in Statin-Intolerant Patients
Significant risk reduction in primary end point of composite of cardiovascular death nonfatal myocardial infarction, nonfatal stroke, coronary revascularization